Former Chief Financial Officer · Lexeo Therapeutics, Inc. (LXEO)

Micah Zajic

FY2023 is the first fiscal year CompBrief holds for Micah Zajic as a named executive officer of Lexeo Therapeutics; the record below is that year, complete. Every figure below is printed as the company filed it and cited to the filing it came from.

Total disclosed compensation, FY2023

$3,064,556

Salary $423,229Bonus $166,000

1st of 4 named executive officers at Lexeo Therapeutics by FY2023 total.

4 named officers on file for Lexeo Therapeutics, FY2023

Micah Zajic’s pay file — $29

  • 1 fiscal year of pay, line by line

A PDF and a CSV sent to your email. Every row is cited to its filing.

One-time report. No refunds.

See an example →

Velarion Intel · free for 3 days · no card

See how Lexeo Therapeutics’s whole pay program stands against its peers

  • Lexeo Therapeutics’s company dashboard and its AI-written, board-ready brief, every figure cited to the filing
  • Peer-group intelligence, custom peer reruns and governance screens
  • Every other company we cover, with alerts when they file
Start my free trial on LXEO→

No card. Nothing is charged, and the trial ends on its own.

Compensation figures as of the proxy filed April 26, 2024 (DEF 14A).

Free

Get Micah Zajic’s pay history as a PDF, right here and by email

The PDF adds what this page leaves out: up to 10 years of pay, a peer comparison, and the board on one page. Two emails at most, nothing else.

Micah Zajic compensation by year

Lexeo Therapeutics Summary Compensation Table · the one fiscal year held
In US dollars, as Lexeo Therapeutics reports it. Most recent year shaded. Totals are the company’s disclosed totals.
ComponentFY2023
Salary$423,229
Bonus$166,000
Option awards$2,464,231
Pension and deferred compensation$0
All other$11,096
Total$3,064,556

Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: Lexeo Therapeutics, Inc. DEF 14A filed April 26, 2024, accession 0000950170-24-048662, and prior-year filings. Open the filing on EDGAR.

How this page was built: the Lexeo Therapeutics, Inc. filed document, accession 0000950170-24-048662. Every figure is read from that document and cited to the page and table it appears in. Filed April 26, 2024.

Lexeo Therapeutics’s named executive officers, FY2023

as the company reported each
Named executive officerRoleFY2023 total
Micah Zajic · this pageFormer Chief Financial Officer$3,064,556
Eric AdlerChief Medical Officer and Head of Research$3,042,824
R. Nolan TownsendChief Executive Officer and Director$1,737,218
Jenny RobertsonChief Business and Legal Officer$1,296,634

The full Lexeo Therapeutics compensation record

free company brief

This page is one person within Lexeo Therapeutics's record. The company brief lists every named executive, each linking to their own page.

Compensation, the day it’s disclosed

The CompBrief Daily Digest lists the newest executive and director compensation disclosures as companies file them.

How this record is built

Every figure on this page is one figure from a public SEC filing, printed as the filing states it and cited to the document. Compensation totals are Lexeo Therapeutics's own disclosed totals, not summed by Velarion. Insider transactions are read from Form 4 filings and cover every line filed since the most recent proxy. Nothing is estimated by Velarion; where the company does not disclose a value the cell reads "—", and a section appears only where the company discloses the data. Corrections: records@velarion.ai.

Micah Zajic's compensation dossier · One-time report. No refunds.